Loading
In 187 Chilean gallbladder cancers stained with breast cancer rules, about one in eight overexpressed HER2, one in five was borderline, and the HER2-positive patients did slightly worse, an early argument for HER2 drugs in this disease.
187 patients with gallbladder cancer (165 women, 22 men) with at least five years of follow-up and 75 controls were studied with an automated immunohistochemical technique using an anti-ErbB2 antibody, scored by the CAP/ASCO criteria for breast cancer.
Overexpression of HER2/neu was observed in 12.8% of cases (0% mucosal, 14.3% muscular, 12.8% subserosal and 10.6% serosal tumours) and equivocal staining in 20%. Overexpression was more frequent in advanced and in better-differentiated tumours (13.8% and 17.4%), not significantly. Patients with overexpression had worse five-year survival than those without (34% versus 41%). The authors concluded that overexpression occurred in 14% of advanced cases and that this subgroup might benefit from HER2 pathway inhibitors.
The largest Chilean HER2 series and the reason HER2 rates in the highest-incidence country are quoted at around 13%; scoring by breast rather than gastric rules explains part of the gap to the Japanese 31%.
Shares HER2 testing in biliary tract cancer (IHC, ISH and NGS), Immunohistochemistry (IHC), HER2, Gallbladder cancer.
Shares HER2 testing in biliary tract cancer (IHC, ISH and NGS), HER2, Gallbladder cancer.
Shares HER2 testing in biliary tract cancer (IHC, ISH and NGS), Immunohistochemistry (IHC), HER2, Gallbladder cancer.
Shares HER2 testing in biliary tract cancer (IHC, ISH and NGS), HER2, Gallbladder cancer.
Shares HER2 testing in biliary tract cancer (IHC, ISH and NGS), Immunohistochemistry (IHC), HER2, Gallbladder cancer.
Shares HER2 testing in biliary tract cancer (IHC, ISH and NGS), HER2, Gallbladder cancer.